Drugs / RD14-01
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05638828 | Dec 2022 → Dec 2023 | neoplasm | Shen Lin | Unknown | No outcome recorded |
| Phase 0 | NCT05444322 | Jul 2022 → Jul 2024 | diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma | He Huang | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05748938 | Feb 2023 → Aug 2024 | cancer | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RD14-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05748938 ↗ |
| Modality | Cell therapy | “Autologous CAR T cells” NCT05444322 ↗ |
| Route | Intravenous | “Infused i.v. in a single dose” NCT05444322 ↗ |
| Target | ROR1 | “ROR1-targeted CAR T-cell therapy” NCT05638828 ↗ |